Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Namrata Mallik

Internal Medicine Moline, IL Medical Doctor

NPI 1750543179 CMS profile 868506

615 Valley View Dr, Suite 204, Moline, IL 61265

Open in the dashboard

General payments

$5,064

277 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Namrata Mallik of Moline, IL is reported in the CMS Open Payments database as having received $5,064 across 277 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $991 49
2024 General $984 51
2023 General $965 59
2022 General $675 33
2021 General $673 35
2020 General $234 14
2019 General $542 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Namrata Mallik
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Namrata Mallik were reported at $991. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Namrata Mallik Internal Medicine median Middle half National median
2019 $542 $159 $48–$570 $163
2020 $234 $119 $33–$402 $114
2021 $673 $135 $37–$521 $132
2022 $675 $141 $42–$496 $149
2023 $965 $149 $45–$519 $160
2024 $984 $154 $47–$537 $164
2025 $991 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $634 34 payments
  2. AbbVie, Inc. $575 31 payments
  3. AstraZeneca Pharmaceuticals LP $489 24 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $464 30 payments
  5. Pfizer Inc. $401 24 payments
  6. GlaxoSmithKline, LLC. $270 16 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $241 14 payments
  8. Astellas Pharma US Inc $185 9 payments
  9. Lilly USA, LLC $176 9 payments
  10. Amgen Inc. $162 9 payments
  11. Other $1,467 77 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,064 277 payments
Products named General payments · program years 2019–2025
  1. Ozempic $514 27 payments
  2. Kerendia $464 30 payments
  3. UBRELVY $438 22 payments
  4. FARXIGA $330 16 payments
  5. TRELEGY ELLIPTA $270 16 payments
  6. NURTEC ODT $266 16 payments
  7. RYBELSUS $222 14 payments
  8. ZAVZPRET $218 13 payments
  9. AIRSUPRA $214 7 payments
  10. SPIRIVA RESPIMAT $185 10 payments
  11. Other $3,409 184 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 124 drugs

Part D claims

8,235

Median for Internal Medicine: 777

Drug cost

$386,279

Median for Internal Medicine: $73,373

Branded share of claims

18.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 82 $85,557
Ozempic Semaglutide Brand 44 $53,125
Eliquis Apixaban Brand 51 $35,882
Januvia Sitagliptin Phosphate Brand 32 $31,277
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 32 $27,257
Breo Ellipta Fluticasone/Vilanterol Brand 31 $12,370
Incruse Ellipta Umeclidinium Bromide Brand 12 $10,995
Tresiba Flextouch U-100 Insulin Degludec Brand 18 $9,818
Trulicity Dulaglutide Brand 12 $9,622
Veozah Fezolinetant Brand 11 $5,948

The 10 drugs with the highest cost, of 124 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$74,710

Of which drugs: $8,121

Medicare patients

206

Average age 73

Services billed

1,042

151 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 45%
Depression 28%
Chronic kidney disease 25%
Ischemic heart disease 24%
Diabetes 23%
COPD 17%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 59 59 $4,827

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $151
$151 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $116
$116 — —
NURTEC ODT
  • PFIZER INC. $83
$83 — —
Veozah
  • Astellas Pharma US Inc $71
$71 11 —
ZAVZPRET
  • PFIZER INC. $66
$66 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

277 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record